Sort
82,697 grants matching “vaccine development”
Abramson Cancer Center of the U of P Core Support Grant
$7,064,076Caryn Lerman · University Of Pennsylvania · P30 · FY2010 · CA
Production of a Broadly Neutralizing HIV Antibodies
$7,055,396Richard Schwartz · National Institute Of Allergy And Infectious Diseases · ZIB · FY2013 · AI
Production of a Broadly Neutralizing HIV Antibody (VRC01)
$7,055,396Richard Schwartz · National Institute Of Allergy And Infectious Diseases · ZIB · FY2012 · AI
Production of a Broadly Neutralizing HIV Antibodies
$7,055,396Richard Schwartz · National Institute Of Allergy And Infectious Diseases · ZIB · FY2014 · AI
Rocky Mountain Regional Center of Excellence or Biodefense and Emerging Infectiou
$7,054,719John T Belisle · Colorado State University · U54 · FY2011 · AI
Advancement of Vaccines and Treatments for Ebola and Marburg Virus Infections
$7,043,167Thomas William Geisbert · University Of Texas Med Br Galveston · U19 · FY2022 · AI
Advancement of Vaccines and Treatments for Ebola and Marburg Virus Infections
$7,043,167Thomas William Geisbert · University Of Texas Med Br Galveston · U19 · FY2023 · AI
Advancement of Vaccines and Treatments for Ebola and Marburg Virus Infections
$7,043,167Thomas William Geisbert · University Of Texas Med Br Galveston · U19 · FY2021 · AI
Advancement of Vaccines and Treatments for Ebola and Marburg Virus Infections
$7,043,167Thomas William Geisbert · University Of Texas Med Br Galveston · U19 · FY2019 · AI
SUBPOPULATIONS AND INTERMEDIATE OUTCOMES IN COPD (SPIROMICS) III
$7,037,497Prescott G Woodruff · University Of California, San Francisco · N01 · FY2025 · HL
Interferon-inducing compounds for use as broad antivirals/adjuvants
$7,036,895Peter Palese · Icahn School Of Medicine At Mount Sinai · N01 · FY2009 · AI
Vaccines and antibodies for arenaviruses
$7,023,024Robert H Carnahan · Vanderbilt University Medical Center · U19 · FY2024 · AI
Consortium for Immunotherapeutics against Emerging Viral Threats
$7,020,842Erica Ollmann Saphire · La Jolla Institute For Immunology · U19 · FY2022 · AI
Pandemic preparedness research and biocontainment infrastructure at The Rockefeller University
$7,019,416Timothy O'Connor · Rockefeller University · G20 · FY2022 · AI
Consortium for AIDS Vaccine Research in Nonhuman Primates
$7,013,564Dan H. Barouch · Beth Israel Deaconess Medical Center · U19 · FY2011 · AI
XIX International AIDS Conference (AIDS 2012)
$7,010,000Chris Beyrer · Ias · R13 · FY2011 · AI
CoVPN 3008 A Phase 3, Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern
$7,007,011Judith S. Currier · University Of California Los Angeles · UM1 · FY2022 · AI
Consortium for Immunotherapeutics against Emerging Viral Threats
$7,006,270Erica Ollmann Saphire · La Jolla Institute For Immunology · U19 · FY2023 · AI
PanCorVac (Center for Pan-Coronavirus Vaccine Development)
$7,000,324Yoshihiro Kawaoka · University Of Wisconsin-Madison · P01 · FY2021 · AI
Consortium for AIDS Vaccine Research in Nonhuman Primates
$6,991,909Dan H. Barouch · Beth Israel Deaconess Medical Center · U19 · FY2012 · AI
Vaccine Immunology Program
$6,981,494Sarah Andrews · National Institute Of Allergy And Infectious Diseases · ZIA · FY2024 · AI
TULANE NATINAL PRIMATE RESEARCH CENTER
$6,979,186Tulane University Of Louisiana · P51 · FY2005 · RR
TULAREMIA VACCINE DEVELOPMENT TEAM
$6,978,780Mark Bolanowski · · N01 · FY2007 · AI
LC: HIV PREVENTION TRIALS NETWORK
$6,974,239Susan H Eshleman · Johns Hopkins University · UM1 · FY2023 · AI
Anti-HIV Broadly Neutralizing Monoclonal Antibody (bnAbs) Drug Substance (DS) Clinical Trial Material Production and Release
$6,969,685David Lindsay · Leidos Biomedical Research, Inc. · N01 · FY2018 · CA